𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Squamous cell carcinoma of temporal bone: Reported on 33 patients

✍ Scribed by Bin Zhang; Guiyi Tu; Guozhen Xu; Pingzhang Tang; Yuhua Hu


Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
65 KB
Volume
21
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis


Background. This study assessed the treatment results of a series of 33 patients with squamous cell carcinoma (SCC) of the temporal bone and evaluated the efficacy of mastoidectomy combined with perioperative radiation therapy protocol.

Methods. Thirty-three patients with biopsy-proven SCC invaded to the temporal bone were reviewed retrospectively and staged into three subgroups according to the University of Pittsburgh TNM Staging System. There were 3 patients with Stage I and II disease(tumor confined to auditory canal), 17 patients with Stage III (tumor involving the middle ear or mastoid), and 13 patients with Stage IV(more extensive disease). Two patients were treated by surgery alone. Eleven patients received irradiation only, and the remaining 20 patients underwent combined surgery and perioperative radiotherapy. The surgical intervention included sleeve resection for patients with Stage I and II lesions and mastoidectomy for all patients with Stage III and IV lesions except 1 who had subtotal temporal bone resection. The radiation dose delivered was in the range of 3500∼10 000 cGy, with an average dose of 6560 cGy.

Results. The five-year survival rate for the whole series was 51.7% by the life-table analysis. After being staged into three subgroups (ie, Stage I + II, Stage III, and Stage IV), the estimated five-year survival rates were 100%, 68.8%, and 19.6%, respec-tively (p = 0.04). Radiation alone yielded a 28.7% five-year survival, while combined surgery and irradiation gave a result of 59.6% (p = 0.80). For patients treated with planned combined therapy, the actuarial five-year survival rates were 72.7% (8/11) for Stage III disease and 12.5% (1/8) for Stage IV disease (p = 0.02). Twelve patients who died of disease did so of local recurrence (10 cases), cervical metastases (1 case), and liver metastases (1 case), with 70% of succumbing to their diseases within two years. Complications include osteonecrosis (n = 1), osteitis (n = 3), radiation dermatitis (n = 2), facial nerve palsy (n = 2), and delayed healing (n = 2). Data on clinical presentation and treatment modality were also analyzed.

Conclusion. The results of mastoidectomy with removal of all gross tumor, combined with planned perioperative irradiation therapy, seems to be a useful approach for SCC of the temporal bone. This gives at least as good, and possibly better, five-year survival than temporal bone resection. The mastoidectomy procedure creates less operative morbidity and mortality. To facilitate the development of more effective means of treating advanced disease, an accepted staging system and cooperative group investigation is necessary.


πŸ“œ SIMILAR VOLUMES


Squamous cell carcinoma of the temporal
✍ Paul W. Gidley; Dianna B. Roberts; Erich M. Sturgis πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 460 KB

## Abstract ## Objectives/Hypothesis: To study the survival outcomes of patients with squamous cell carcinoma (SCC) of the temporal bone. A secondary purpose was to evaluate the University of Pittsburgh staging system as a predictor of survival. ## Study Design: Retrospective review. ## Methods

Planned fractionated boron neutron captu
✍ Shin-Ichi Haginomori; Shin-Ichi Miyatake; Takaki Inui; Michitoshi Araki; Shinji πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 519 KB

## Abstract ## Background. We describe the first case of extensive squamous cell carcinoma in the temporal bone recurring after surgery, conventional radiotherapy, and chemotherapy, which was treated using planned fractionated boron neutron capture therapy (BNCT). ## Methods. A 42‐year‐old patie

Impact of comorbidity on outcome of youn
✍ Bhuvanesh Singh; Mahesh Bhaya; Marc Zimbler; Jordan Stern; J. Thomas Roland; Ric πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 77 KB πŸ‘ 3 views

Background. Comorbid conditions have a significant impact on the actuarial survival of patients with head and neck cancer. However, no studies have evaluated the impact of comorbidity on tumor-and treatment-specific outcomes. This study was performed to evaluate the impact of comorbidity, graded by